Incyte Enters Agreement with CMS on Medicaid Pricing for Jakafi and Jakafi XR

Summary of Filing: Incyte Corporation (Form 8-K)

Filing Date: August 31, 2026
Report Date: August 31, 2026
Item Reported: Item 8.01 (Other Events)

---

Key Disclosures

1. CMS Agreement on Jakafi and Jakafi XR:

   • Incyte Corporation entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (CMS).
   • Under the terms, state Medicaid programs will receive access to Jakafi® and Jakafi XR® at pricing benchmarked against a defined group of advanced, industrialized countries.

2. Exemption from Future Pricing Mandates:

   • In exchange, Incyte expects that it will not be subject to certain prospective CMS drug-pricing models and mandates, specifically highlighting the proposed GUARD and GLOBE models.

3. Financial Impact:

   • Incyte confirmed that the agreement is not expected to affect its 2026 financial guidance.
   • The company does not anticipate any material adverse impact on its long-term financial outlook.